Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.60 |
| ▸ | HTR2B | P41595 | 3/20 | 0.60 |
| ▸ | HTR2C | P28335 | 2/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.54 |
| ▸ | DRD3 | P35462 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7612638 | 0.89 | HTR2A (0.66) | HTR2AHTR2BHTR2CADRA2CSLC6A4 | |
| SCHEMBL13235906 | 0.85 | HTR2A (0.64) | HTR2AHTR2BHTR2CADRA2CSLC6A4 | |
| SCHEMBL27274983 | 0.84 | HTR2A (0.67) | HTR2AHTR2BHTR2CADRA2CSLC6A4 | |
| SCHEMBL15881786 | 0.84 | HTR2A (0.67) | HTR2AHTR2BHTR2CADRA2CSLC6A4 | |
| SCHEMBL27774511 | 0.82 | HTR2A (0.53) | HTR2AHTR2BHTR2CADRA2CSLC6A4 | |
| Nordexfenfluramine SCHEMBL16673896 | 0.82 | HTR2A (0.84) | HTR2AHTR2BHTR2CADRA2CSLC6A4 | |
| Nordexfenfluramine SCHEMBL16673917 | 0.82 | HTR2A (0.84) | HTR2AHTR2BHTR2CADRA2CSLC6A4 | |
| SCHEMBL12440296 | 0.81 | HTR2A (0.59) | HTR2AHTR2BHTR2CADRA2CSLC6A4 | |
| SCHEMBL27810056 | 0.80 | MEN1 (0.52) | HTR2AHTR2BHTR2CADRA2CSLC6A4 | |
| SCHEMBL31273982 | 0.80 | HTR2A (0.60) | HTR2AHTR2BHTR2CADRA2CSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | HTR2A 1960/4885HTR2B 1710/4885HTR2C 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.